The SNMMI Practice Guideline for Therapy of Thyroid Disease with 131I 3.0*

Preamble……1 I. Introduction: patient management, licensure.……2 II. Goals.……2 III. Definitions: risk levels……2 IV. Common clinical indications……3 V. Qualifications and responsibilities of personnel (in the United States).……3 VI. Procedure/specifications of the

[1]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[2]  Z. Hall.  Cancer , 1906, The Hospital.

[3]  M. Sonenberg,et al.  The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.

[4]  T. K. Natarajan,et al.  Validation of a rapid computerized method of measuring 99mTc pertechnetate uptake for routine assessment of thyroid structure and function. , 1973, The Journal of clinical endocrinology and metabolism.

[5]  P. Schneider.  Simple, rapid thyroid function testing with 99mTc-pertechnetate thyroid uptake ratio and neck/thigh ratio. , 1979, AJR. American journal of roentgenology.

[6]  K. Burman,et al.  Radioiodine treatment of Graves' disease. An assessment of its potential risks. , 1986, Annals of internal medicine.

[7]  R. K. Bull,et al.  Stopping powers for electrons and positrons: ICRU Report 37; 271 pp.; 24 figures; U.S. $24.00. , 1986 .

[8]  F. Datz.  Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  I. Fogelman,et al.  Radioiodine treatment of solitary functioning thyroid nodules. , 1986, The British journal of radiology.

[10]  I. Carrió,et al.  Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. , 1987, Clinical nuclear medicine.

[11]  J. D. Harrison,et al.  Radiation Dose to Patients from Radiopharmaceuticals , 1988 .

[12]  J. Romaldini,et al.  Adverse Effects Related to Thionamide Drugs and Their Dose Regimen , 1989, The American journal of the medical sciences.

[13]  Keith F. Eckerman,et al.  Mird: Radionuclide Data and Decay Schemes , 1989 .

[14]  K. Johansen,et al.  Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  E. Bergstralh,et al.  Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. , 1993, Surgery.

[16]  M. Sperling,et al.  Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. , 1993, Nuclear medicine and biology.

[17]  P. Larsen,et al.  Maternal and Fetal Thyroid Function , 1994 .

[18]  J. Barentsz,et al.  Large, Compressive Goiters Treated with Radioiodine , 1994, Annals of Internal Medicine.

[19]  Hanan Abd El-Razik.  Radioiodine therapy , 1994 .

[20]  M. Dottorini,et al.  Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  M. Dottorini,et al.  Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  J. Konishi,et al.  Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma. , 1997, Thyroid : official journal of the American Thyroid Association.

[23]  R. Sparks,et al.  Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals. , 1997, Health physics.

[24]  P. Zanzonico,et al.  Radiation dose to patients and relatives incident to 131I therapy. , 1997, Thyroid : official journal of the American Thyroid Association.

[25]  M. Doody,et al.  Cancer Mortality Following Treatment for Adult Hyperthyroidism , 1998 .

[26]  M. Doody,et al.  Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. , 1998, JAMA.

[27]  A. Hermus,et al.  Treatment of benign nodular thyroid disease. , 1998, The New England journal of medicine.

[28]  L. Hegedüs,et al.  The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. , 1999, The Journal of clinical endocrinology and metabolism.

[29]  S. Larson,et al.  [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. , 1999, The Journal of clinical endocrinology and metabolism.

[30]  P. Kirchner,et al.  Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  K. Ain,et al.  Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. , 1999, The Journal of clinical endocrinology and metabolism.

[32]  M. Stabin,et al.  Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  P. Grigsby,et al.  Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma. , 2000, JAMA.

[34]  H. Schirrmeister,et al.  Anatomical distribution and sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. , 2001, Thyroid : official journal of the American Thyroid Association.

[35]  A. Maia,et al.  The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. , 2001, The Journal of clinical endocrinology and metabolism.

[36]  G. Braunstein,et al.  The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. , 2001, The Journal of clinical endocrinology and metabolism.

[37]  H. Palmedo,et al.  Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  S. Larson,et al.  A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[40]  D. Cooper,et al.  The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. , 2002, Thyroid : official journal of the American Thyroid Association.

[41]  P. Larsen,et al.  High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. , 2002, The Journal of clinical endocrinology and metabolism.

[42]  G. Wiseman,et al.  Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[43]  C. Harmer,et al.  Testicular dose and fertility in men following I131 therapy for thyroid cancer , 2002, Clinical endocrinology.

[44]  M. Dempsey,et al.  Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[45]  G. Lindstedt,et al.  Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone , 2002, Journal of endocrinological investigation.

[46]  S. Mandel,et al.  Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.

[47]  E. Kebebew,et al.  Locally advanced differentiated thyroid cancer. , 2003, Surgical oncology.

[48]  J. Romijn,et al.  Effects of low‐iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma , 2003, Clinical endocrinology.

[49]  Michael R. Tuttle,et al.  Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinoma. , 2003, Thyroid : official journal of the American Thyroid Association.

[50]  W. Leslie,et al.  A randomized comparison of radioiodine doses in Graves' hyperthyroidism. , 2003, The Journal of clinical endocrinology and metabolism.

[51]  G. Palù,et al.  Gene therapy for thyroid cancer , 2004, Expert opinion on biological therapy.

[52]  Henrik S. Thomsen,et al.  Effect of iodinated contrast media on thyroid function in adults , 2004, European Radiology.

[53]  P. Grigsby,et al.  Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  M. Saghari,et al.  Gonadal function in patients with differentiated thyroid cancer treated with (131)I. , 2004, Hellenic journal of nuclear medicine.

[55]  P. Roach,et al.  Diagnostic I-123 scintigraphy to assess potential breast uptake of I-131 before radioiodine therapy in a postpartum woman with thyroid cancer. , 2004, Clinical nuclear medicine.

[56]  A. Pinchera,et al.  Outcome of radioiodine‐131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study , 2005, Clinical endocrinology.

[57]  N. Tamaki,et al.  Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  J. Jonklaas,et al.  Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. , 2005, Thyroid : official journal of the American Thyroid Association.

[59]  M. McBride,et al.  Second primary cancers in thyroid cancer patients: a multinational record linkage study. , 2006, The Journal of clinical endocrinology and metabolism.

[60]  E. Mazzaferri.  Managing small thyroid cancers. , 2006, JAMA.

[61]  D. van Nostrand,et al.  The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[62]  A. Cangır,et al.  Iodine 131 thyroid ablation in female children and adolescents: Long-term risk of infertility and birth defects , 1994, Annals of Surgical Oncology.

[63]  V. Guimarães,et al.  Testicular function after radioiodine therapy in patients with thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.

[64]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[65]  J. Jonklaas,et al.  Outcomes of patients with differentiated thyroid carcinoma following initial therapy. , 2006, Thyroid : official journal of the American Thyroid Association.

[66]  Division on Earth.  Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2 , 2006 .

[67]  M. Brzozowska,et al.  Timing and Potential Role of Diagnostic I-123 Scintigraphy in Assessing Radioiodine Breast Uptake Before Ablation in Postpartum Women With Thyroid Cancer: A Case Series , 2006, Clinical nuclear medicine.

[68]  S. Larson,et al.  Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[69]  R. Wahl,et al.  Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[70]  F. Pacini,et al.  Clinical features and therapeutic implication of papillary thyroid microcarcinoma. , 2007, Thyroid : official journal of the American Thyroid Association.

[71]  J. Siegel,et al.  LICENSEE OVER-RELIANCE ON CONSERVATISMS IN NRC GUIDANCE REGARDING THE RELEASE OF PATIENTS TREATED WITH 131I , 2007, Health physics.

[72]  E. Silberstein.  Comparison of Outcomes After 123I Versus 131I Preablation Imaging Before Radioiodine Ablation in Differentiated Thyroid Carcinoma , 2007, Journal of Nuclear Medicine.

[73]  Takeo Ishigaki,et al.  Comparison of 18F-FDG PET and Bone Scintigraphy in Detection of Bone Metastases of Thyroid Cancer , 2007, Journal of Nuclear Medicine.

[74]  T. Pilli,et al.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. , 2007, The Journal of clinical endocrinology and metabolism.

[75]  J. Tward,et al.  The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.

[76]  S. Larson,et al.  The value of positron emission tomography (PET) in the management of patients with thyroid cancer. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[77]  T. Kuwert,et al.  Impact of I-131-SPECT/spiral-CT on nodal staging of differentiated thyroid carcinoma at first radioablation , 2008 .

[78]  M. Beheshti,et al.  Posttherapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[79]  M. Zanchetta,et al.  Optimum recombinant human thyrotropin dose in patients with differentiated thyroid carcinoma and end-stage renal disease. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[80]  M. Schlumberger,et al.  Therapeutic Administration of 131I for Differentiated Thyroid Cancer: Radiation Dose to Ovaries and Outcome of Pregnancies , 2008, Journal of Nuclear Medicine.

[81]  R. Kloos,et al.  Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. , 2008, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[82]  S. Larson,et al.  Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008, Journal of Nuclear Medicine.

[83]  Quan-Yong Luo,et al.  Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma , 2008, Journal of Nuclear Medicine.

[84]  E. Silberstein.  Reducing the Incidence of 131I-Induced Sialadenitis: The Role of Pilocarpine , 2008, Journal of Nuclear Medicine.

[85]  M. Luster,et al.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[86]  M. Dietlein,et al.  Graves' disease and radioiodine therapy , 2008, Nuklearmedizin.

[87]  K. Frey,et al.  Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma. , 2009, The British journal of radiology.

[88]  W. Bautz,et al.  Impact of 131I SPECT/Spiral CT on Nodal Staging of Differentiated Thyroid Carcinoma at the First Radioablation , 2008, Journal of Nuclear Medicine.

[89]  Chao Ma,et al.  Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[90]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[91]  D. van Nostrand,et al.  The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[92]  C. Benbassat,et al.  Well-differentiated thyroid carcinoma: comparison of microscopic and macroscopic disease. , 2009, Thyroid : official journal of the American Thyroid Association.

[93]  M. Uder,et al.  Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[94]  T. Fahey,et al.  Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two? , 2009, Thyroid : official journal of the American Thyroid Association.

[95]  N. Heutte,et al.  Clinical relevance of single-photon emission computed tomography/computed tomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.

[96]  Glenn D. Flux,et al.  A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[97]  S. Janković,et al.  Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131. , 2009, Thyroid : official journal of the American Thyroid Association.

[98]  Pedagógia.  University of Iowa Hospitals and Clinics , 2010 .

[99]  M. Mete,et al.  (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. , 2010, Thyroid : official journal of the American Thyroid Association.

[100]  P. Tran,et al.  I-131 Treatment of Graves' Disease in an Unsuspected First Trimester Pregnancy; the Potential for Adverse Effects on the Fetus and a Review of the Current Guidelines for Pregnancy Screening , 2010, International journal of pediatric endocrinology.

[101]  M. Drouet,et al.  Radiation victim management and the haematologist in the future: Time to revisit therapeutic guidelines? , 2010, International journal of radiation biology.

[102]  T. Heusner,et al.  Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[103]  Markus Luster,et al.  Dosimetry and thyroid cancer: the individual dosage of radioiodine. , 2010, Endocrine-related cancer.

[104]  G. Kahaly,et al.  The tale of radioiodine and Graves' orbitopathy. , 2010, Thyroid : official journal of the American Thyroid Association.

[105]  K. Koral,et al.  Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. , 2010, AJR. American journal of roentgenology.

[106]  John T. Chang,et al.  The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. , 2010, Thyroid : official journal of the American Thyroid Association.

[107]  Han-Sin Jeong,et al.  Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections. , 2010, Surgery.

[108]  Seiichi Yamamoto,et al.  Development of a high resolution Si-PM based compact gamma camera system , 2011 .

[109]  H. Schöder,et al.  Thyroid cancer--indications and opportunities for positron emission tomography/computed tomography imaging. , 2011, Seminars in nuclear medicine.

[110]  K. Friedman,et al.  I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with I-131 in post-thyroidectomy thyroid cancer patients. , 2011, Thyroid : official journal of the American Thyroid Association.

[111]  A. Pinchera,et al.  Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake. , 2011, Thyroid : official journal of the American Thyroid Association.

[112]  D. Delbeke,et al.  Conjoint Statement of the SNM, ACNM, and ABNM on Credentialing and Delineation of Privileges for Therapeutic Procedures Using Radiopharmaceuticals , 2011, The Journal of Nuclear Medicine.

[113]  Caroline E Esaias,et al.  A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. , 2011, International journal of radiation oncology, biology, physics.

[114]  G. Antoch,et al.  Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[115]  S. Larson,et al.  Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH , 2011, The Journal of clinical endocrinology and metabolism.

[116]  Victor M Montori,et al.  Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. , 2011, Thyroid : official journal of the American Thyroid Association.

[117]  E. Silberstein.  The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. , 2011, Seminars in nuclear medicine.

[118]  X. Rabasseda.  Society of Nuclear Medicine and Molecular Imaging (SNMMI) St. Louis, Missouri, USA - June 7-11, 2014 , 2014 .